- Home
- ORMP vs ASRT Comparison
ORMP vs ASRT Comparison
Compare ORMP & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORMP | ASRT |
|---|---|---|
| Founded | 2002 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.1M | 76.0M |
| IPO Year | 2010 | 2004 |
Fundamental Metrics
Financial Performance| Metric | ORMP | ASRT |
|---|---|---|
| Price | $3.42 | $11.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 155.7K | 24.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.40% | N/A |
| EPS Growth | N/A | ★ 95.07 |
| EPS | ★ 1.26 | N/A |
| Revenue | $1,340,000.00 | ★ $124,961,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.42 |
| P/E Ratio | $2.68 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.82 | $0.51 |
| 52 Week High | $3.76 | $12.95 |
Technical Indicators
Market Signals| Indicator | ORMP | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 51.57 | 50.67 |
| Support Level | $3.22 | $11.05 |
| Resistance Level | $3.76 | $12.45 |
| Average True Range (ATR) | 0.21 | 0.46 |
| MACD | -0.01 | -0.15 |
| Stochastic Oscillator | 37.88 | 38.46 |
Price Performance
Historical ComparisonAbout ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.